Evocutis has launched a highly-defined panel of 36 strains of Propionibacterium acnes to improve the reliability of testing undertaken during anti-acne or anti-spot product research and development.
The testing of anti-acne and blemishreduction products for antimicrobial activity against P. acnes is a recognised method for determining potential efficacy, but is usually performed against a single strain. With a robust panel of clinically relevant strains, Evocutis can now offer healthcare and pharmaceutical companies developing antiacne and anti-spot ingredients or products a more reliable R&D selection tool. Importantly, the panel includes strains resistant to antibiotics commonly used in treating acne, thus indicating whether test materials would be able to help reduce the prevalence of antibiotic resistance. The P. acnes panel complements a range of research testing services offered by Evocutis which includes LabSkin, a living skin equivalent technology, as well as a clinical volunteer testing service
